Skip to main content

ILEU20019/20190014/ Kristen O'Dwyer

Basic Study Information

The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).

Location: University of Rochester Cancer Center

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search